ADORA2A
Overview
ADORA2A encodes the adenosine A2A receptor (A2AR), a G-protein-coupled receptor that suppresses T cell effector function in adenosine-rich tumor microenvironments. In the context of anti-tumor immunity, adenosine signaling through A2AR represents an immunosuppressive axis exploited by tumors; blocking this receptor is a therapeutic strategy to restore T cell activity.
Alterations observed in the corpus
- A2AR antagonism by ILB-2109 (selective A2AR antagonist) combined with toripalimab is under phase Ib/IIa investigation in NPC, targeting adenosine-mediated immunosuppression in the TME PMID:24952746
Cancer types (linked)
- NPC: A2AR implicated in T-cell exhaustion via adenosine-rich TME; therapeutic antagonism under clinical investigation PMID:24952746
Co-occurrence and mutual exclusivity
No data in current corpus.
Therapeutic relevance
- ILB-2109 (selective A2AR antagonist) + toripalimab — phase Ib/IIa in NPC PMID:24952746
Open questions
No conflicts in current corpus.
Sources
This page was processed by entity-page-writer on 2026-05-11.